Brief: Ocuphire Presents APX3330 Zeta-1 Clinical Data In Late-Breaker Session
27/06/2023 14:42
June 27 (Reuters) - Ocuphire Pharma Inc OCUP.O :
* OCUPHIRE PRESENTS APX3330 ZETA-1 CLINICAL DATA IN
LATE-BREAKER
SESSION AT THE AMERICAN DIABETES ASSOCIATION’S ANNUAL CONFERENCE
* OCUPHIRE PHARMA INC - APX3330 ACHIEVED STATISTICAL
SIGNIFICANCE
IN PREVENTING CLINICALLY MEANINGFUL PROGRESSION OF DIABETIC
RETINOPATHY
* OCUPHIRE PHARMA INC - ZETA-1 WAS A MULTICENTER
DOUBLE-MASKED
PHASE 2 TRIAL COMPARING APX3330 TO PLACEBO IN 103 PATIENTS
* OCUPHIRE PHARMA INC - APX3330 DID NOT MEET PRIMARY
ENDPOINT
Source text for Eikon: ID:nGNX7C6lcR
Further company coverage: OCUP.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Opus Genetics
See all newsUS RESEARCH ROUNDUP-Affiliated Managers Group, Goldman Sachs, Vaxcyte
Health Rounds: Experimental eye drops ease night vision problems for drivers
U.S. STOCKS ON THE MOVE-Apple, Omnicom, Jersey Mike's Subs
U.S. STOCKS ON THE MOVE-Airbnb, Lyft, Korn Ferry
Opus Genetics hits 5-year high on positive early- to mid-stage eye disease gene therapy data